Yi-You Huang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2735768/publications.pdf

Version: 2024-02-01

20 papers	484 citations	687363 13 h-index	752698 20 g-index
20 all docs	20 docs citations	20 times ranked	576 citing authors

#	Article	IF	Citations
1	Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis. Journal of Medicinal Chemistry, 2022, 65, 4238-4254.	6.4	10
2	Structure-based optimization of Toddacoumalone as highly potent and selective PDE4 inhibitors with anti-inflammatory effects. Biochemical Pharmacology, 2022, 202, 115123.	4.4	2
3	Discovery of Highly Specific Catalytic-Site-Targeting Fluorescent Probes for Detecting Lysosomal PDE10A in Living Cells. ACS Chemical Biology, 2021, 16, 857-863.	3.4	1
4	Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis. Journal of Medicinal Chemistry, 2021, 64, 9537-9549.	6.4	7
5	Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety. Journal of Medicinal Chemistry, 2021, 64, 13736-13751.	6.4	12
6	Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket. Journal of Medicinal Chemistry, 2020, 63, 9828-9837.	6.4	27
7	Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension. Acta Pharmaceutica Sinica B, 2020, 10, 2339-2347.	12.0	17
8	Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors. ACS Chemical Neuroscience, 2020, 11, 1058-1071.	3.5	7
9	Discovery and Optimization of Î±-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia. Journal of Medicinal Chemistry, 2020, 63, 3370-3380.	6.4	20
10	Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 3707-3721.	6.4	26
11	Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation. Bioorganic and Medicinal Chemistry, 2018, 26, 119-133.	3.0	11
12	Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structureâ€“Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension. Journal of Medicinal Chemistry, 2018, 61, 8468-8473.	6.4	21
13	The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from Selaginella pulvinata. Biochemical Pharmacology, 2017, 130, 51-59.	4.4	35
14	Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay. Journal of Chemical Information and Modeling, 2017, 57, 355-364.	5.4	40
15	Natural phosphodiesterase-4 inhibitors from the leaf skin of Aloe barbadensis Miller. FÃ¬toterapÃ¬Ã¢, 2015, 100, 68-74.	2.2	23
16	Natural phosphodiesterase-4 (PDE4) inhibitors from Crotalaria ferruginea. FÃ¬toterapÃ¬Ã¢, 2014, 94, 177-182.	2.2	17
17	Selaginpulvilins Aâ€“D, New Phosphodiesterase-4 Inhibitors with an Unprecedented Skeleton from Selaginella pulvinata. Organic Letters, 2014, 16, 282-285.	4.6	77
18	Prenylated Coumarins: Natural Phosphodiesterase-4 Inhibitors from Toddalia asiatica. Journal of Natural Products, 2014, 77, 955-962.	3.0	60

#	Article	IF	Citations
19	Chemical constituents of Aloe barbadensis Miller and their inhibitory effects on phosphodiesterase-4D. FÃ¬toterapÃ¬Ã¢, 2013, 91, 159-165.	2.2	39
20	The Molecular Basis for the Selectivity of Tadalafil toward Phosphodiesterase 5 and 6: A Modeling Study. Journal of Chemical Information and Modeling, 2013, 53, 3044-3053.	5.4	32